Understand the source comparison
Follistatin-344 vs Follistatin-288: Research Application Differences
Before comparing follistatin isoforms, understand that both derive from the same gene but serve different physiological roles due to structural differences. The table below outlines their distinct characteristics and research applications. Structure 288 amino
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before comparing follistatin isoforms, understand that both derive from the same gene but serve different physiological roles due to structural differences. The table below outlines their distinct characteristics and research applications.
- Structure
- 288 amino acids, heparin-binding domain present
- 344 amino acids, acidic C-terminal tail, no heparin-binding domain
- The heparin-binding domain determines tissue retention vs systemic circulation
- Tissue Distribution
- Binds extracellular matrix and cell surfaces, remains tissue-localized
- Circulates systemically, distributes broadly across tissues
- Use 344 for systemic myostatin inhibition studies, 288 for localized effects
- Half-Life (Murine)
- Highly tissue-bound, minimal systemic clearance
- ~3–4 hours in circulation
- Shorter half-life requires repeated dosing for sustained systemic effects
- Primary Binding Targets
- Myostatin, activin (tissue-localized antagonism)
- Myostatin, activin (systemic antagonism)
- Both isoforms bind the same targets but at different anatomical scales
- Research Applications
- Localized muscle regeneration, wound healing, fibrosis models
- Muscle wasting, cachexia, metabolic disease, age-related sarcopenia
- Application choice depends on whether the research question is local or systemic
- Delivery Route Typical
- Intramuscular or direct tissue injection
- Subcutaneous or intravenous for systemic distribution
- Delivery route should match isoform distribution characteristics
- Bottom Line
- Follistatin-288 remains where you inject it; follistatin-344 circulates and reaches distant tissues. For systemic myostatin inhibition research, 344 is the isoform of choice. For localized tissue studies. Regeneration, fibrosis. 288's tissue-binding property is advantageous.
- The choice between isoforms determines experimental outcomes. A study examining follistatin's effect on diaphragm muscle wasting in a mechanical ventilation model would likely choose follistatin-344 for systemic delivery, ensuring the diaphragm receives circulating follistatin even though it's anatomically distant from a subcutaneous injection site. Conversely, a wound healing study examining follistatin's effect on dermal fibroblast activity would choose follistatin-288, injected directly into the wound bed, to maximize local concentration without systemic distribution.
- Serum follistatin levels in healthy adult humans range from 1.5–6 ng/mL, measured by ELISA. These levels reflect endogenous follistatin-344 primarily, as follistatin-288 is largely tissue-sequestered and doesn't circulate significantly. Exogenous follistatin-344 administration in research models achieves serum levels 10–50× baseline depending on dose, with muscle tissue concentrations lagging serum by 2–4 hours post-injection. Dosing in published murine studies ranges from 0.5 mg/kg to 10 mg/kg administered via subcutaneous or intravenous routes, with higher doses producing greater muscle mass increases but also higher off-target activin inhibition. Which can affect reproductive function and metabolic parameters.